drug
midazolam
Marketedupdated 3mo agoby UCB SA
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
Epilepsy
all catalysts(0)
nothing on the calendar yet
Trials studying midazolam
- phase1A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin
- phase1An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers
- phase1Drug-Interaction Assessment of GSK3772701 in Healthy Male and Female Participants Aged 18 to 55 Years
- phase1A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
- phase1A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
- phase2An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
- phase3A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 18, 2028
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jun 20, 2038formulationUS 10966990
- Jun 20, 2038formulationUS 10966990
- Jan 18, 2028formulationUS 82170331.4y
- Jan 18, 2028formulationUS 88093221.4y
- Jan 18, 2028formulationUS 92894321.4y
- Jan 18, 2028formulationUS 96874951.4y
FDA exclusivities (1)
- May 17, 2026ODE-243Orphan Drug (7y)
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that